TG Therapeutics Raises 2026 Outlook As Briumvi Drives Concentrated Growth
TG Therapeutics has raised its revenue guidance for 2026, primarily due to the strong performance of its multiple sclerosis drug, Briumvi. The company is actively pursuing new autoimmune indications for Briumvi, indicating a strategic focus on expanding its core product's market reach. While this approach concentrates both opportunity and risk, investors are showing confidence, with the stock up 29% in the past three months.
TGTX stock hits fresh 52-week high – here’s why retail is bullish despite Q1 earnings miss
This article discusses TG Therapeutics (TGTX) stock hitting a new 52-week high, driven by retail investor bullishness. This optimism persists despite the company reporting an earnings miss for its first quarter, suggesting other factors are influencing investor sentiment.
Technical Reactions to TGTX Trends in Macro Strategies
This article analyzes the technical trends for Tg Therapeutics Inc. (NASDAQ: TGTX), noting conflicting sentiment across different time horizons and elevated downside risk. It provides AI-generated trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis, support, and resistance levels. The analysis suggests choppy market conditions for TGTX.
TGTX stock hits fresh 52-week high – here’s why retail is bullish despite Q1 earnings miss
This article discusses TG Therapeutics (TGTX) stock hitting a new 52-week high despite an earnings miss in Q1. The bullish sentiment among retail investors appears to be driven by factors beyond recent financial results.
Stronger Earnings And Higher BRIUMVI Guidance Might Change The Case For Investing In TG Therapeutics (TGTX)
TG Therapeutics (TGTX) recently reported strong first-quarter 2026 results, with revenue of US$204.92 million and net income of US$19.78 million, and subsequently raised its full-year 2026 revenue target to about US$925 million, largely driven by increased expectations for BRIUMVI U.S. net product revenue. This update reinforces BRIUMVI's central role in the company's financial outlook and highlights both the opportunity and the inherent risk of dependence on a single key product. Investors now have a clearer quarterly checkpoint for BRIUMVI's scaling with a Q2 2026 target of US$220 million in U.S. net product revenue.
Earnings call transcript: TG Therapeutics Q1 2026 misses EPS, stock surges
TG Therapeutics (NASDAQ:TGTX) reported a significant miss on Q1 2026 EPS and slightly lower-than-expected revenue; however, its stock surged by over 19% in pre-market trading, driven by strong U.S. BRIUMVI net product revenue that exceeded guidance. The company highlighted robust year-over-year growth in BRIUMVI sales, consistent sequential growth, and increasing investor confidence in its long-term potential, including pipeline advancements like the subcutaneous BRIUMVI program and expansion into new indications. Executives provided optimistic guidance for future quarters, emphasizing strategic investments in R&D and marketing, and continuing share repurchases.
Earnings call transcript: TG Therapeutics Q1 2026 misses EPS, stock surges
TG Therapeutics reported a significant miss on Q1 2026 EPS at $0.12 against an expected $0.28, and revenue slightly below forecast at $194.8 million. Despite this, the stock surged over 19% in pre-market trading, driven by strong U.S. BRIUMVI net product revenue exceeding guidance and robust year-over-year operational improvements. The company also raised its full-year U.S. revenue guidance, repurchased $100 million in stock, and highlighted ongoing developments for subcutaneous BRIUMVI and pipeline expansion.
A Look At TG Therapeutics (TGTX) Valuation After Record Q1 Revenue And Higher 2026 Guidance
TG Therapeutics (TGTX) has seen increased attention and a rally in its stock price following record Q1 2026 revenue driven by BRIUMVI, a raised full-year 2026 revenue outlook of US$925 million, and progress in Phase 3 clinical trials. The stock is currently trading about 12% below the average analyst price target, with a fair value pegged at $44.43 per share, suggesting it might still be undervalued. An upcoming catalyst is the planned launch of subcutaneous BRIUMVI, expected to significantly expand its market reach.
TG Therapeutics (TGTX) Q1 2026 Results Put 66% Net Margin Narrative To The Test
TG Therapeutics (TGTX) recently released its Q1 2026 results, showing revenue of US$204.9 million, basic EPS of US$0.14, and net income of US$19.8 million. The company's trailing twelve-month net profit margin stands at 66%, leading investors to question the sustainability of this high profitability given forecasts of slower earnings growth compared to revenue growth. The article highlights the conflicting narratives between bullish investors focusing on long-term growth and bearish critics concerned about product concentration and potential margin compression.
TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance
TG Therapeutics reported strong first-quarter 2026 financial results, with total global revenue of approximately $205 million, driven by BRIUMVI U.S. net revenue of $194.8 million. The company significantly raised its full-year 2026 revenue guidance for BRIUMVI U.S. net product to $885-$900 million, citing strong demand and commercial execution. TG Therapeutics also highlighted pipeline progress, including completed patient enrollment for subcutaneous BRIUMVI and a consolidated dosing regimen for IV BRIUMVI, along with securing $500 million in non-dilutive capital.
Is Briumvi-Driven Earnings Growth Altering The Investment Case For TG Therapeutics (TGTX)?
TG Therapeutics reported strong Q1 2026 results, with significant revenue and net income growth driven by Briumvi. This performance, coupled with the upcoming launch of a subcutaneous formulation of Briumvi, reinforces the company's investment narrative, although competitive pressures remain a key concern. The company's future growth and valuation are heavily reliant on Briumvi's continued market penetration and the success of its new formulation.
Number of shareholders of TG Therapeutics, Inc. – LSX:A1JXW7
This article focuses on the number of shareholders for TG Therapeutics, Inc. (LSX:A1JXW7) and provides financial data and other market information related to the company. The content appears to be a stub or a data-focused page from TradingView, awaiting detailed shareholder data for different periods. It highlights the company's listing on the Lang & Schwarz Exchange under the Health Technology/Pharmaceuticals sector.
TG Therapeutics Stock 6-Day Winning Spree: Stock Climbs 28%
TG Therapeutics (TGX) stock has experienced a significant 6-day winning streak, resulting in a 28% increase in its stock price. The article highlights this notable price performance for the company.
TG Therapeutics, Inc. 1Q 2026: Revenue $204.92M, EPS $0.12— 10-Q Summary
TG Therapeutics, Inc. (TGTX) reported strong first-quarter 2026 results, with revenue reaching $204.92 million and diluted EPS of $0.12, reflecting significant year-over-year growth. This surge was primarily driven by the continued commercial expansion of BRIUMVI in the U.S. and growing international sales. The company also made progress in its pipeline with completed enrollment for a Phase 3 study of subcutaneous ublituximab and an ongoing Phase 1 azer-cel program.
TG Therapeutics (TGTX) Q1 2026 Results Put 66% Net Margin Narrative To The Test
TG Therapeutics (TGTX) has reported its Q1 2026 results, showing revenue of US$204.9 million, basic EPS of US$0.14, and net income of US$19.8 million. The company's trailing twelve-month net profit margin is 66%, indicating substantial profitability, though quarterly EPS has been volatile. This performance tests the narrative around the sustainability of its high margins, especially with forecasts suggesting earnings growth will trail revenue growth.
TG Therapeutics Inc at JPMorgan Healthcare Conference Transcript
This document contains the transcript from TG Therapeutics Inc's presentation at the JPMorgan Healthcare Conference held on January 13, 2026. The session featured CEO Michael Weiss, introduced by senior biotech analyst Lut Ming Cheng, for a presentation followed by a live audience Q&A. The detailed content beyond the introduction requires a GuruFocus subscription.
TG Therapeutics, Inc. (NASDAQ:TGTX) Q1 2026 Earnings Call Transcript
TG Therapeutics (NASDAQ:TGTX) reported its Q1 2026 earnings, exceeding revenue guidance with $195 million in U.S. BRIUMVI net product revenue, and raising full-year U.S. revenue guidance to $885 million to $900 million. The company highlighted strong 63% year-over-year growth, record new patient enrollments for BRIUMVI, and significant progress in its pipeline, including late-stage studies for subcutaneous BRIUMVI and an allogeneic anti-CD19 CAR-T for progressive MS. Analysts questioned the impact of potential new treatments, the cadence of clinical trial data, and the company's capital allocation strategy, which includes share buybacks and strategic business development.
TG Therapeutics Up Over 14%, on Pace for Largest Percent Increase Since August 2024 -- Data Talk
TG Therapeutics (TGTX) stock saw a significant increase of over 14%, putting it on track for its largest percentage gain since August 2024. The stock also experienced higher trading volume compared to its 65-day average, indicating increased investor interest. This surge places TGTX among other top performers in the biotechnology sector.
TG Therapeutics (NASDAQ: TGTX) lifts 2026 BRIUMVI sales and revenue guidance
TG Therapeutics (NASDAQ: TGTX) reported strong first-quarter 2026 results, with total revenues of $204.9 million, significantly exceeding expectations, driven by robust BRIUMVI sales for multiple sclerosis. This performance led the company to raise its full-year 2026 total global revenue guidance to approximately $925 million and its BRIUMVI U.S. net product revenue guidance to $885–900 million. The company's financials also showed increased profitability and a strong cash position, supporting ongoing commercialization and pipeline development, including a subcutaneous version of BRIUMVI.
Earnings Flash (TGTX) TG Therapeutics, Inc. Reports Q1 Revenue $204.9M, Vs. FactSet Est of $200.3M
TG Therapeutics, Inc. (TGTX) announced its Q1 revenue reached $204.9 million, surpassing the FactSet estimate of $200.3 million. This indicates a stronger-than-expected financial performance for the quarter, exceeding analyst projections for the biopharmaceutical company.
TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance
TG Therapeutics reported strong first-quarter 2026 financial results, with total global revenue of approximately $205 million and U.S. BRIUMVI net revenue of $194.8 million, representing a 63% increase year-over-year. Driven by strong demand and new patient starts, the company significantly raised its full-year 2026 total global revenue target to $925 million and its U.S. BRIUMVI net product revenue target to $885-900 million. TG Therapeutics also highlighted recent progress in its pipeline, including completed patient enrollment for subcutaneous BRIUMVI and a consolidated IV dosing regimen, and secured an additional $500 million in non-dilutive capital.
TG Therapeutics Surges 11.3% After HC Wainwright & Co. Maintains Buy
TG Therapeutics' shares surged by 11.3% on Wednesday after HC Wainwright & Co. raised its price target for the biotechnology company from $60 to $70, while reiterating a Buy rating. This upgrade, coupled with signals of a product contract, indicates growing confidence in the stock's potential upside. The company's market capitalization reached $6.3 billion amid significant trading volume following the analyst's endorsement.
TG Therapeutics outlines $925M 2026 global revenue guidance while targeting ~$220M Q2 US BRIUMVI net revenue
TG Therapeutics has provided an updated global net revenue guidance for its drug BRIUMVI, projecting $925 million for 2026, an increase from previous estimates. The company is also targeting approximately $220 million in U.S. net revenue for BRIUMVI in the second quarter of the current year. This revised outlook indicates strong expected growth and market penetration for their key multiple sclerosis treatment.
Is Briumvi-Driven Earnings Growth Altering The Investment Case For TG Therapeutics (TGTX)?
TG Therapeutics reported strong Q1 2026 results with significant revenue and net income growth, primarily driven by Briumvi for multiple sclerosis. This performance reinforces the company's investment narrative around Briumvi, especially with the upcoming subcutaneous formulation launch. However, the narrative also highlights the ongoing risk of intense competition and payer pressure potentially impacting Briumvi's pricing and market share.
TG THERAPEUTICS ($TGTX) Releases Q1 2026 Earnings
TG THERAPEUTICS ($TGTX) reported its Q1 2026 earnings, with earnings per share of $0.17, missing estimates of $0.30. However, the company's revenue of $204,920,000 exceeded the estimated $200,750,575. The article also details recent insider trading activity, institutional holdings changes, and analyst price targets for TGTX.
TG Therapeutics: Q1 Earnings Snapshot
TG Therapeutics Inc. reported first-quarter net income of $19.8 million, or 12 cents per share, missing Wall Street expectations. Adjusted earnings were 17 cents per share, contrasting with analysts' estimate of 23 cents. However, the biopharmaceutical company's revenue of $204.9 million surpassed Street forecasts, and they project full-year revenue of $925 million.
TG Therapeutics: Q1 Earnings Snapshot
TG Therapeutics Inc. (TGTX) reported first-quarter net income of $19.8 million, or 12 cents per share, which adjusted to 17 cents per share, missing Wall Street expectations of 23 cents. However, the biopharmaceutical company's revenue of $204.9 million surpassed Street forecasts of $199.3 million. TG Therapeutics forecasts full-year revenue of $925 million.
Vanguard Group Inc. Has $472.22 Million Stock Position in TG Therapeutics, Inc. $TGTX
Vanguard Group Inc. increased its stake in TG Therapeutics, Inc. by 2.1% during the fourth quarter, bringing its total ownership to 15,841,002 shares valued at $472.22 million. The biopharmaceutical company reported an EPS of $0.17 for the quarter, missing analyst estimates, and currently holds a "Moderate Buy" consensus rating with a target price around $50. Other institutional investors also adjusted their positions, and 58.58% of the stock is held by hedge funds and institutions.
TG Therapeutics Jumps 5.1% Amid Sector-Wide Rally
TG Therapeutics (TGTX) saw its stock climb 5.1% on Monday, closing at $35.56, as part of a broader biotechnology sector rally. This increase, which occurred without any company-specific news, pushed its market capitalization to $5.7 billion. The article suggests investors should monitor future clinical trial data, regulatory decisions, or commercial updates to determine if the stock's gains are sustainable, given the lack of specific catalysts.
Assessing TG Therapeutics (TGTX) Valuation As BRIUMVI Subcutaneous Launch Potential Draws Focus
TG Therapeutics (TGTX) has garnered investor attention following recent stock performance, with the company’s valuation drawing focus ahead of the potential launch of subcutaneous BRIUMVI. Despite recent market volatility, analysts suggest the stock could be 24% undervalued, with a fair value pegged at $44.43 compared to the current price of $33.85. This optimism largely hinges on the expanded market access and revenue growth anticipated from the new BRIUMVI formulation.
CapEx per share of TG Therapeutics, Inc. – LSX:A1JXW7
This article provides access to the Capital Expenditure (CapEx) per share data for TG Therapeutics, Inc. (LSX:A1JXW7) on the TradingView platform. It highlights the availability of financial metrics for the company on the Lang & Schwarz Exchange. The content is primarily a data placeholder, with the actual CapEx values to be displayed on the TradingView interface.
TG Therapeutics, Inc. (NASDAQ:TGTX) Given Average Rating of "Moderate Buy" by Analysts
TG Therapeutics, Inc. (NASDAQ:TGTX) has received a consensus "Moderate Buy" rating from six analysts, with an average 1-year price target of $50.00. While some analysts, like Goldman Sachs, have raised price targets, others, such as Wall Street Zen and JPMorgan Chase & Co., have either downgraded the stock or trimmed price targets. The company recently missed Q4 EPS estimates but saw a significant 78% year-over-year revenue increase, and institutional investors hold a substantial portion of its stock.
Pictet Asset Management Holding SA Trims Stock Position in TG Therapeutics, Inc. $TGTX
Pictet Asset Management Holding SA reduced its stake in TG Therapeutics (NASDAQ:TGTX) by 9.2% in the fourth quarter, selling 148,503 shares and retaining 1,461,048 shares valued at $43.55 million. Meanwhile, other institutional investors like Vanguard Group Inc. increased their holdings, with institutional investors collectively owning 58.58% of the company's stock. TG Therapeutics, a clinical-stage biopharmaceutical company, reported a Q4 EPS miss but a 78% year-over-year revenue increase with analysts maintaining a "Moderate Buy" consensus and an average price target of $50.00.
TG Therapeutics schedules Q1 results call, 2026 outlook for May 6
TG Therapeutics (NASDAQ: TGTX) announced it will host a conference call on Wednesday, May 6, 2026, at 8:30 AM ET to discuss its first-quarter 2026 financial results and provide a business outlook for the remainder of 2026. The call will be hosted by Chairman and CEO Michael S. Weiss, with financial results released via press release prior to the event. Investors can access a live webcast and a 30-day audio replay on the company's Investors & Media Events page.
TG Therapeutics to Host Conference Call on First Quarter 2026 Financial Results and Business Update
TG Therapeutics, Inc. (NASDAQ: TGTX) will host a conference call on Wednesday, May 6, 2026, at 8:30 AM ET to discuss its first-quarter 2026 financial results and provide a business outlook. Michael S. Weiss, Chairman and CEO, will lead the call. The company, a commercial-stage biotechnology firm, focuses on treatments for B-cell diseases and has FDA approval for BRIUMVI® (ublituximab-xiiy) for relapsing forms of multiple sclerosis.
TG Therapeutics to Host Conference Call on First Quarter 2026 Financial Results and Business Update
TG Therapeutics, Inc. (NASDAQ: TGTX) announced it will host a conference call on Wednesday, May 6, 2026, at 8:30 AM ET to discuss its first-quarter 2026 financial results and provide a business outlook. Michael S. Weiss, Chairman and CEO, will lead the call, which will also be accessible via webcast and replay on the company's website. The company is a commercial-stage biotechnology firm focused on treatments for B-cell diseases, with an FDA-approved drug, BRIUMVI, for relapsing forms of multiple sclerosis.
TG Therapeutics (NasdaqCM:TGTX) Stock Forecast & Analyst Predictions
TG Therapeutics (TGTX) is forecast to grow earnings by 11% and revenue by 21.6% per annum. The company's EPS is expected to grow by 7.5% annually, with a projected return on equity of 56.9% in three years. Analyst price targets have seen mixed adjustments, with some firms trimming targets while others have raised them, reflecting updated views on sector conditions, growth assumptions, and company-specific data catalysts, particularly for its drug BRIUMVI.
Vanguard Portfolio Management discloses 5.26% stake in TG Therapeutics (NASDAQ: TGTX)
Vanguard Portfolio Management has disclosed a 5.26% passive stake in TG Therapeutics (NASDAQ: TGTX) through a Schedule 13G filing. As of March 31, 2026, Vanguard beneficially owns 8,400,210 shares, primarily for Vanguard funds and managed accounts. The firm holds sole dispositive power over all these shares and sole voting power over 126,231 shares.
TG Therapeutics Inc (TGTX) News, Articles, Events & Latest Updates
This article provides a compilation of recent news and updates regarding TG Therapeutics Inc (TGTX). Key topics include upcoming Q1 earnings reports, analysts revising earnings expectations, and institutional investors like M&T Bank Corp and JPMorgan Chase & Co. adjusting their stakes in the company. Additionally, the article notes the completion of enrollment in a Phase III study for Briumvi and the company's "Moderate Buy" consensus recommendation from analysts.
M&T Bank Corp Buys Shares of 125,789 TG Therapeutics, Inc. $TGTX
M&T Bank Corp acquired 125,789 shares of TG Therapeutics (NASDAQ:TGTX) in the fourth quarter, a new stake valued at approximately $3.75 million. Institutional investors now own about 58.58% of the biopharmaceutical company's stock, with several other hedge funds also increasing their positions. Despite missing recent EPS estimates, analysts maintain a "Moderate Buy" consensus with a $50 price target.
TG Therapeutics secures $750M credit facility with Blue Owl, boosts buyback to $300M
TG Therapeutics has secured a $750 million credit facility with Blue Owl Capital to enhance financial flexibility and support potential strategic initiatives. Concurrently, the company increased its share repurchase program from $100 million to $300 million, aiming to return value to shareholders. This move follows a strong financial performance in 2023, driven by the success of its drug, Briumvi.
TG Therapeutics (TGTX) Is Up 7.6% After Advancing Subcutaneous BRIUMVI Phase 3 Trial Enrollment Completion
TG Therapeutics (TGTX) saw its stock price increase by 7.6% following the completion of enrollment for a Phase 3 trial of a subcutaneous formulation of BRIUMVI. This trial aims to evaluate an every 8- and 12-week dosing schedule against the current intravenous regimen for relapsing multiple sclerosis, potentially offering a more convenient administration. The advancement of this formulation is critical for the company's growth, as it could expand BRIUMVI's market into self-administered treatments and mitigate pricing pressure from other at-home therapies, thereby influencing TG Therapeutics' future earnings durability.
TG Therapeutics (TGTX) Is Up 7.6% After Advancing Subcutaneous BRIUMVI Phase 3 Trial Enrollment Completion
TG Therapeutics (TGTX) saw a 7.6% stock increase after completing enrollment for its Phase 3 trial of a subcutaneous BRIUMVI formulation for relapsing multiple sclerosis. This advancement is crucial as it could lead to a more convenient, self-administered treatment, addressing market shifts towards at-home therapies and potentially enhancing the company's financial durability. The company's 2025 revenue from BRIUMVI reached US$616.287 million, demonstrating its profitability and setting the stage for future growth influenced by this trial's outcome.
(TGTX) Volatility Zones as Tactical Triggers
This article analyzes Tg Therapeutics Inc. (NASDAQ: TGTX) using AI models to identify volatility zones and tactical triggers for trading strategies. It highlights strong near and mid-term sentiment but a weak long-term outlook, noting elevated downside risk due to a lack of long-term support signals. The analysis provides specific entry, target, and stop-loss zones for position trading, momentum breakout, and risk hedging strategies.
Q1 EPS Estimates for TG Therapeutics Cut by HC Wainwright
HC Wainwright has cut its Q1 2026 EPS estimates for TG Therapeutics (NASDAQ:TGTX) to $0.17 from $0.24, also trimming estimates for subsequent quarters and the full fiscal year 2026. This downward revision signals weaker expected momentum for the biopharmaceutical company, whose recent quarterly earnings missed consensus estimates. Despite a "Moderate Buy" average rating from analysts, several firms have recently lowered price targets or downgraded the stock.
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting
TG Therapeutics announced presentations of new data for BRIUMVI (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS) at the American Academy of Neurology 2026 annual meeting. The data, from the ENABLE and ENHANCE studies, highlight BRIUMVI's real-world effectiveness, safety, tolerability, and optimized dosing approaches. BRIUMVI is a novel glycoengineered monoclonal antibody approved for treating RMS in adults.
New BRIUMVI studies in relapsing MS to be shown at AAN 2026
TG Therapeutics (NASDAQ: TGTX) announced data presentations for BRIUMVI (ublituximab-xiiy) in relapsing multiple sclerosis (RMS) at the American Academy of Neurology 2026 annual meeting. The presentations will cover real-world outcomes from the Phase 4 ENABLE observational study and provide dosing and safety updates from the ENHANCE study, further supporting BRIUMVI's differentiated profile, effectiveness, safety, and tolerability. Michael S. Weiss, CEO of TG Therapeutics, highlighted the importance of these studies in expanding the body of evidence for BRIUMVI as a significant treatment option for adults with RMS.
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting
TG Therapeutics announced presentations of new data for BRIUMVI (ublituximab-xiiy) in relapsing forms of multiple sclerosis (RMS) at the American Academy of Neurology 2026 annual meeting. The data from the ENABLE and ENHANCE studies highlight BRIUMVI's effectiveness, safety, and tolerability, as well as providing insights into optimized dosing. BRIUMVI is a novel glycoengineered monoclonal antibody indicated for treating adults with RMS.
HC Wainwright Forecasts Lower Earnings for TG Therapeutics
HC Wainwright has revised its Q2 2026 EPS forecast for TG Therapeutics (NASDAQ:TGTX) downwards to $0.20 from $0.27, although the biopharmaceutical company's current stock performance remains positive. Despite missing previous analyst EPS estimates, TG Therapeutics reported a significant year-over-year revenue increase of 78%. The company holds a "Moderate Buy" consensus rating with a target price of $50.00, reflecting a mixed but generally optimistic outlook from other analysts.
Assessing TG Therapeutics (TGTX) Valuation After BRIUMVI Phase 3 Subcutaneous Trial Milestone
TG Therapeutics (TGTX) has completed enrollment for a Phase 3 trial of a subcutaneous version of BRIUMVI for multiple sclerosis, a development that could expand its market significantly. The company is currently considered 20.5% undervalued, with its shares trading at US$35.33 against a narrative fair value of US$44.43. While current financials show strong revenue and net income, the valuation hinges on successful BRIUMVI launch and managing payer pressures.
